New Delhi, March 27 -- Pharmaceutical companies,together with most other firms,werenot spared by the coronavirus sell-off. However,mosthavenot beenasbadly scarredasmanyf ront-line stocks. In the past three months, the Nifty Pharmaindex slipped13.6%, contrastedw ith theNifty50'ssteep 28.7%plunge. Forawhile now, the sector hasbeens truckdown, so investor perception that stocks arenow inexpensiveseemsappropriate. Thesector's decentdomesticdemand growth continues.Sales in February rebounded, registering12.1%growthyear-onyear.Interestingly,pharmavolumes pickedup adecent 3.8% in February,accordingtodata fromAIOCDAwacs,againstsuccessivedeclines in the twomonthsprior.Nevertheless,the key will be whether such astep-upinvolumes persists."Ap ick-up in...